Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 1,036: | Line 1,036: | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | | | ||
|SG | |SG | ||
| | |4/12/2023 by FQR | ||
|SP (prior AE); 2021 template added | |SP (prior AE); 2021 template added | ||
|- | |- | ||
| Line 1,045: | Line 1,045: | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | | | ||
|SG | |SG | ||
| | |4/12/2023 by FQR | ||
|SP (prior AE); 2021 template added | |SP (prior AE); 2021 template added | ||
|- | |- | ||
| Line 1,185: | Line 1,185: | ||
|- | |- | ||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera | ||
| | | | ||
| | | | ||
|Complete | |||
| | | | ||
|SG | |SG | ||
| | |4/12/23 by FQR | ||
|SP (prior AE); 2021 template added | |SP (prior AE); 2021 template added | ||
|- | |- | ||